Invesco Ltd. Olema Pharmaceuticals, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 15,155 shares of OLMA stock, worth $81,382. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,155

Previous 15,482 2.11%

Holding current value

$81,382

Previous $167,000 7.78%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$10.41 - $16.46 $3,404 - $5,382	-327 Reduced 2.11%	15,155 $180,000
Q2 2024 Aug 13, 2024	BUY	$8.73 - $13.99 $4,286 - $6,869	491 Added 3.28%	15,482 $167,000
Q1 2024 May 14, 2024	SELL	$10.95 - $16.62 $118,358 - $179,645	-10,809 Reduced 41.9%	14,991 $169,000
Q4 2023 Feb 12, 2024	SELL	$10.53 - $17.14 $4.01 Million - $6.53 Million	-380,942 Reduced 93.66%	25,800 $361,000
Q3 2023 Nov 13, 2023	BUY	$8.19 - $12.98 $562,857 - $892,050	68,725 Added 20.33%	406,742 $5.02 Million
Q2 2023 Aug 11, 2023	BUY	$3.22 - $9.65 $1.09 Million - $3.26 Million	338,017 New	338,017 $3.05 Million
Q4 2021 Feb 14, 2022	SELL	$8.75 - $30.71 $72,301 - $253,756	-8,263 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$22.96 - $30.13 $5.54 Million - $7.27 Million	-241,314 Reduced 96.69%	8,263 $228,000
Q2 2021 Aug 17, 2021	BUY	$21.15 - $36.14 $66,812 - $114,166	3,159 Added 1.28%	249,577 $6.98 Million
Q1 2021 May 17, 2021	SELL	$27.81 - $53.64 $7.89 Million - $15.2 Million	-283,582 Reduced 53.51%	246,418 $8.18 Million
Q4 2020 Feb 16, 2021	BUY	$37.09 - $54.5 $19.7 Million - $28.9 Million	530,000 New	530,000 $25.5 Million

Others Institutions Holding OLMA

# of Institutions

136

Shares Held

58.8M

Call Options Held

141K

Put Options Held

23.1K

View Full List

About Olema Pharmaceuticals, Inc.

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $217M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

More about OLMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account